Blood pressure control and left ventricular hypertrophy in long-term CAPD and hemodialysis patients: a

Ali Ihsan Günal1, Erdogan Ilkay, Ercan Kirciman

  • 1Department of Nephrology, Firat University Medical School, Elazig, Turkey. igunal@yahoo.com

Insights

Hypertension and left ventricular hypertrophy (LVH) are similar in continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) patients. Strict volume and blood pressure control are key to achieving comparable cardiac outcomes in both dialysis modalities.

Area of Science:

  • Nephrology
  • Cardiology
  • Internal Medicine

Background:

  • The prevalence of hypertension and left ventricular hypertrophy (LVH) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD) versus hemodialysis (HD) remains unclear.
  • Assessing cardiac structure and function differences between dialysis modalities is crucial for patient management.

Purpose of the Study:

  • To compare cardiac performance indices between patients on CAPD and HD.
  • To investigate the long-term effects of dialysis modality on cardiac parameters.

Main Methods:

  • Compared cardiac performance in 50 HD patients and 34 CAPD patients.
  • Subdivided patients into long-term (over 60 months) HD and CAPD groups for further analysis.
  • Evaluated parameters including blood pressure, cardiothoracic index, left atrial index, left ventricular chamber size, wall thickness, left ventricular mass index (LVMI), and isovolumic relaxation time (IVRT).

Main Results:

  • No significant differences in blood pressure or cardiothoracic index were observed between CAPD and HD patients.
  • Left ventricular mass index (LVMI) and chamber dimensions were similar in both groups.
  • No significant differences in cardiac structure or function were found between long-term HD and CAPD subgroups.

Conclusions:

  • Continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) have comparable effects on cardiac structure and function.
  • Achieving normovolemia and normotension through strict volume control is essential for similar cardiac outcomes.
  • Antihypertensive drug use may influence observed differences, highlighting the importance of volume management.
Abstract

Related Concept Videos

Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...